Navigation Links
Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors

BRANFORD, Conn., Dec. 15, 2010 /PRNewswire/ -- HistoRx announces that Jack Davis has accepted its invitation to join the Board of Directors.  As the former President and CEO of both a diagnostic product company and a laboratory testing company, he is an acknowledged diagnostic industry expert.

Mr. Davis was Co-founder, President, CEO and eventually Chairman of the Board at Dianon Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services and disease management systems focusing on cancer, pre-natal genetics and cytogenetics.  Dianon Systems was sold to LabCorp in 2002.  In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO.  Previously, he was Division Vice President and worldwide General Manager of Abbott Laboratories Diagnostics Products business unit.

HistoRx CEO Rana K. Gupta approached Mr. Davis with the opportunity, commenting, "Now that HistoRx has proven our license model for diagnostics commercialization, it's crucial to expand our expertise in both the laboratory services business and the diagnostic product arena since these are the avenues of distribution we will continue to pursue.  Jack's experience with running Abbott's worldwide Diagnostics Products business and with building a national anatomic pathology services business at Dianon make him a valuable addition to the HistoRx Board."

"I'm delighted to join the board of directors of HistoRx, a company that, working with the Pathology community at large, is committed to improving the objectivity, reproducibility and quantitation of anatomic pathology," Davis stated. "Testing services based on AQUA technology are improving the quality of care in cancer diagnostics."

About HistoRx (

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care.  The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis.  AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making.  HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  For more information please visit

SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
2. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
3. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
7. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
8. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth
11. Life Sciences Company Sword Diagnostics Moves Operations to Chicago
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):